SARS-CoV-2 (COVID-19) is a new strain of coronavirus that is regarded as a respiratory disease and is transmittable among humans. At present, the disease has caused a pandemic, and COVID-19 cases are ballooning out of control. The impact of such turbulent situations can be controlled by tracking the patterns of infected and death cases through accurate prediction and by taking precautions accordingly. We collected worldwide COVID-19 case information and successfully predicted infected victims and possible death cases around the world and in the United States. In addition, we analyzed some leading stock market shares and successfully forecast their trends. We also scrutinized the share market price by proper reasoning and considered the state of affairs of COVID-19, including geographical dispersity. We publicly release our developed dashboard that presents statistical data of COVID-19 cases, shows predicted results, and reveals the impact of COVID-19 on leading companies and different countries' job markets.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314859 | PMC |
| http://dx.doi.org/10.1016/j.patter.2021.100315 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction Mucormycosis is an uncommon fungal infection caused by filamentous fungi of the Mucorales order, namely Rhizopus, Lichthemia, andMucor species. The incidence and prevalence of mucormycosis reached an all-time high during the COVID-19 pandemic due to excessive steroid use and other factors, leading to the coining of the term CAM (COVID Associated Mucormycosis). The diagnosis of mucormycosis is by a combination of histopathology and microbiological techniques, such as KOH mount and culture.
View Article and Find Full Text PDFTemporal pattern and effect of COVID-19 on the trend of TB, DRTB, paediatrics TB and TB with HIV Coinfection: A decadal trend analysis.
J Family Med Prim Care
December 2024
Department of Community Medicine, Mahatma Gandhi Medical College, Jaipur, Rajasthan, India.
Background: India shares 2/3 of global TB burden. MDR and HIV coinfections are the main obstacle in achieving the successful TB control because it decrease the therapy effect.
Objective: To analyze the long-term trends of incidence of tuberculosis cases and identify any differences between actual and projected cases after the COVID-19 pandemic.
Assessing the mask-wearing habit as a contributing factor for COVID-19-associated mucormycosis.
J Family Med Prim Care
December 2024
Department of Oral Medicine and Radiology, Post Graduate Institute of Dental Sciences Rohtak, Haryana, India.
Introduction: Association of mask-wearing habit and mucormycosis.
Context: During the second wave of the COVID-19 pandemic, there was an absurd surge in cases of mucormycosis. COVID-19-associated mucormycosis (CAM) was found to be associated with the presence of diabetes, use of systemic steroids, prolonged use of masks, and others.
Prevalence and control of hypertension in COVID-19 positive cases.
J Family Med Prim Care
December 2024
Health Education and Promotion, Faculty of Public Health and Health Informatics, Umm Al-Qura University, Alziziah Makkah, Saudi Arabia.
Background: The coronavirus disease (COVID-19) is an infectious disease caused by the newly discovered SARS-CoV-2 virus. Patients diagnosed with COVID-19 experience several complications including hypertension or elevated blood pressure which is a serious medical condition that significantly increases the risks of heart, brain, and kidney diseases.
Objectives: To assess the prevalence and control of hypertension in COVID-19 patients.
Monitoring SARS-CoV-2 variants with complementary surveillance systems: risk evaluation of the Omicron JN.1 variant in France, August 2023 to January 2024.
Euro Surveill
January 2025
National Reference Center for Respiratory Viruses, Hospices Civils de Lyon, CIRI, INSERM U1111, University Claude Bernard Lyon 1, Lyon, France.
BackgroundEarly detection and characterisation of SARS-CoV-2 variants have been and continue to be essential for assessing their public health impact. In August 2023, Santé publique France implemented enhanced surveillance for BA.2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!